Institution
British Heart Foundation
Nonprofit•London, United Kingdom•
About: British Heart Foundation is a nonprofit organization based out in London, United Kingdom. It is known for research contribution in the topics: Population & Heart failure. The organization has 1585 authors who have published 2141 publications receiving 101808 citations. The organization is also known as: BHF.
Topics: Population, Heart failure, Myocardial infarction, Coronary artery disease, Ejection fraction
Papers published on a yearly basis
Papers
More filters
TL;DR: A meta-analysis of published and unpublished data found that statin therapy is associated with a slightly increased risk of development of diabetes, but the risk is low both in absolute terms and when compared with the reduction in coronary events.
1,986 citations
Uppsala University1, British Heart Foundation2, University of Erlangen-Nuremberg3, University of Oslo4, Royal Adelaide Hospital5, Bosch6, Seoul National University7, University of Helsinki8, University of São Paulo9, Innsbruck Medical University10, University of Alberta11, Aarhus University12, University of Copenhagen13, University of Gothenburg14, Akdeniz University15, Charles University in Prague16, University of Silesia in Katowice17, University of Zurich18, AstraZeneca19
TL;DR: In patients undergoing hemodialysis, the initiation of treatment with rosuvastatin lowered the LDL cholesterol level but had no significant effect on the composite primary end point of death from cardiovascular causes, nonf fatal myocardial infarction, or nonfatal stroke.
Abstract: BACKGROUND: Statins reduce the incidence of cardiovascular events in patients at high cardiovascular risk. However, a benefit of statins in such patients who are undergoing hemodialysis has not bee ...
1,789 citations
TL;DR: This article provided a Europe-wide update on the current burden of cardiovascular disease and specifically of coronary heart disease and stroke in Europe, and the overall picture and the distribution of the burden, continues to evolve in a developing Europe.
Abstract: This overview provides a Europe-wide update on the current burden of cardiovascular disease, and specifically of coronary heart disease and stroke. Cardiovascular disease continues to cause a large proportion of deaths and disability in Europe, and places a substantial burden on the health care systems and economies of Europe. The overall picture, and the distribution of the burden, continues to evolve in a developing Europe. There have been major improvements in recent years on many measures of cardiovascular disease; however, these improvements have not been universal, and substantial inequalities persist.
1,786 citations
Brigham and Women's Hospital1, Harvard University2, Massachusetts Institute of Technology3, Lund University4, Icahn School of Medicine at Mount Sinai5, Mayo Clinic6, Centro Nacional de Investigaciones Cardiovasculares7, British Heart Foundation8, University of Cambridge9, Wellcome Trust10, University of Pennsylvania11
TL;DR: The presence of CHIP in peripheral‐blood cells was associated with nearly a doubling in the risk of coronary heart disease in humans and with accelerated atherosclerosis in mice.
Abstract: BackgroundClonal hematopoiesis of indeterminate potential (CHIP), which is defined as the presence of an expanded somatic blood-cell clone in persons without other hematologic abnormalities, is common among older persons and is associated with an increased risk of hematologic cancer. We previously found preliminary evidence for an association between CHIP and atherosclerotic cardiovascular disease, but the nature of this association was unclear. MethodsWe used whole-exome sequencing to detect the presence of CHIP in peripheral-blood cells and associated such presence with coronary heart disease using samples from four case–control studies that together enrolled 4726 participants with coronary heart disease and 3529 controls. To assess causality, we perturbed the function of Tet2, the second most commonly mutated gene linked to clonal hematopoiesis, in the hematopoietic cells of atherosclerosis-prone mice. ResultsIn nested case–control analyses from two prospective cohorts, carriers of CHIP had a risk of c...
1,536 citations
TL;DR: Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs.
1,308 citations
Authors
Showing all 1603 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| John J.V. McMurray | 178 | 1389 | 184502 |
| Mark E. Cooper | 158 | 1463 | 124887 |
| Naveed Sattar | 155 | 1326 | 116368 |
| Paul Elliott | 153 | 773 | 103839 |
| Nilesh J. Samani | 149 | 779 | 113545 |
| Paul M. Matthews | 140 | 617 | 88802 |
| John G.F. Cleland | 137 | 1172 | 110227 |
| David G. Harrison | 137 | 492 | 72190 |
| Karl Swedberg | 136 | 706 | 111214 |
| Keith A.A. Fox | 136 | 830 | 95960 |
| John Danesh | 135 | 394 | 100132 |
| Ian Ford | 134 | 678 | 85769 |
| Hugh Watkins | 128 | 524 | 91317 |
| Adrian Bauman | 127 | 1061 | 91151 |
| Andrew J.S. Coats | 127 | 820 | 94490 |